<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02677116</url>
  </required_header>
  <id_info>
    <org_study_id>15841</org_study_id>
    <secondary_id>I5B-MC-JGDN</secondary_id>
    <nct_id>NCT02677116</nct_id>
  </id_info>
  <brief_title>A Study of Olaratumab Alone and in Combination With Standard Chemotherapies in Children With Cancer</brief_title>
  <official_title>A Phase 1, Open-Label, Dose-Escalation Study of Olaratumab as a Single Agent and in Combination With Doxorubicin, Vincristine/Irinotecan, or High-Dose Ifosfamide in Pediatric Patients With Relapsed or Refractory Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this study is to evaluate the safety of different doses of olaratumab and
      to determine which dose should be used for future pediatric studies. The present study is
      open to children with advanced cancer or cancer that has spread to another part of the body.
      The study has three parts. In the first two parts, a specific dose of olaratumab will be
      given in 21 day cycles, followed by one of three standard chemotherapy regimens. In the third
      part, a specific dose of olaratumab will be given with one of three standard chemotherapy
      regimens in 21 day cycles. Participants will only enroll in one part.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2016</start_date>
  <completion_date type="Anticipated">June 2019</completion_date>
  <primary_completion_date type="Anticipated">June 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants with Olaratumab Dose Limiting Toxicities (DLTs)</measure>
    <time_frame>Parts A and B: Cycle 1 through Cycle 2 in each arm (21 day cycle); Part C: Cycle 1 only (21 day cycle)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK): Maximum Concentration (Cmax) of Olaratumab</measure>
    <time_frame>Cycle 1 through Cycle 2 in each arm (21 day cycles; up to 42 days total)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK): Trough Serum Concentration (Cmin) of Olaratumab</measure>
    <time_frame>Cycle 1 through Cycle 5 in each arm (21 day cycles; up to 105 days total)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Participants With a Complete or Partial Response (Objective Response Rate [ORR])</measure>
    <time_frame>Baseline to objective progression or start of new anti-cancer therapy (estimated up to 6 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival</measure>
    <time_frame>Baseline to objective progression or death from any cause (estimated up to 6 months)</time_frame>
  </secondary_outcome>
  <number_of_arms>11</number_of_arms>
  <enrollment type="Anticipated">79</enrollment>
  <condition>Neoplasm Metastasis</condition>
  <arm_group>
    <arm_group_label>Olaratumab Alone (Part A)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Olaratumab administered intravenously (IV) on Days 1 and 8 for one cycle (21 days).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Olaratumab + Doxorubicin (Part A)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One cycle of olaratumab alone (administered IV on Days 1 and 8). For all subsequent cycles, olaratumab administered IV on Days 1 and 8 and doxorubicin administered IV on Days 1 and 2. All cycles are 21 days. Treatment will cease when discontinuation criterion is met.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Olaratumab + Vincristine + Irinotecan (Part A)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One cycle of olaratumab alone (administered IV on Days 1 and 8). For all subsequent cycles, olaratumab and vincristine administered IV on Days 1 and 8. Irinotecan administered IV on Days 1 through 5. All cycles are 21 days. Treatment will cease when discontinuation criterion is met.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Olaratumab + Ifosfamide (Part A)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One cycle of olaratumab alone (administered IV on Days 1 and 8). For all subsequent cycles, olaratumab administered IV on Days 1 and 8 of each cycle. Ifosfamide administered IV on Days 1 though 5. All cycles are 21 days. Treatment will cease when discontinuation criterion is met.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Olaratumab Alone (Part B)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Olaratumab administered intravenously (IV) on Days 1 and 8 for one cycle (21 days).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Olaratumab + Doxorubicin (Part B)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One cycle of olaratumab alone (administered IV on Days 1 and 8). For all subsequent cycles, olaratumab administered IV on Days 1 and 8 and doxorubicin administered IV on Days 1 and 2. All cycles are 21 days. Treatment will cease when discontinuation criterion is met.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Olaratumab + Vincristine + Irinotecan (Part B)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One cycle of olaratumab alone (administered IV on Days 1 and 8). For all subsequent cycles, olaratumab and vincristine administered IV on Days 1 and 8. Irinotecan administered IV on Days 1 through 5. All cycles are 21 days. Treatment will cease when discontinuation criterion is met.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Olaratumab + Ifosfamide (Part B)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One cycle of olaratumab alone (administered IV on Days 1 and 8). For all subsequent cycles, olaratumab administered IV on Days 1 and 8 of each cycle. Ifosfamide administered IV on Days 1 though 5. All cycles are 21 days. Treatment will cease when discontinuation criterion is met.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Olaratumab + Doxirubicin (Part C)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Olaratumab administered IV on Days 1 and 8 and doxorubicin administered IV on Days 1 and 2. All cycles are 21 days. Treatment will cease when discontinuation criterion is met.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Olaratumab + Vincristine + Irinotecan (Part C)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Olaratumab and vincristine administered IV on Days 1 and 8. Irinotecan administered IV on Days 1 through 5. All cycles are 21 days. Treatment will cease when discontinuation criterion is met.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Olaratumab + Ifosfamide (Part C)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Olaratumab administered IV on Days 1 and 8 of each cycle. Ifosfamide administered IV on Days 1 though 5. All cycles are 21 days. Treatment will cease when discontinuation criterion is met.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Olaratumab</intervention_name>
    <description>Olaratumab administered IV.</description>
    <arm_group_label>Olaratumab Alone (Part A)</arm_group_label>
    <arm_group_label>Olaratumab + Doxorubicin (Part A)</arm_group_label>
    <arm_group_label>Olaratumab + Vincristine + Irinotecan (Part A)</arm_group_label>
    <arm_group_label>Olaratumab + Ifosfamide (Part A)</arm_group_label>
    <arm_group_label>Olaratumab Alone (Part B)</arm_group_label>
    <arm_group_label>Olaratumab + Doxorubicin (Part B)</arm_group_label>
    <arm_group_label>Olaratumab + Vincristine + Irinotecan (Part B)</arm_group_label>
    <arm_group_label>Olaratumab + Ifosfamide (Part B)</arm_group_label>
    <arm_group_label>Olaratumab + Doxirubicin (Part C)</arm_group_label>
    <arm_group_label>Olaratumab + Vincristine + Irinotecan (Part C)</arm_group_label>
    <arm_group_label>Olaratumab + Ifosfamide (Part C)</arm_group_label>
    <other_name>LY3012207</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxorubicin</intervention_name>
    <description>Doxorubicin administered IV.</description>
    <arm_group_label>Olaratumab + Doxorubicin (Part A)</arm_group_label>
    <arm_group_label>Olaratumab + Doxorubicin (Part B)</arm_group_label>
    <arm_group_label>Olaratumab + Doxirubicin (Part C)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vincristine</intervention_name>
    <description>Vincristine administered IV.</description>
    <arm_group_label>Olaratumab + Vincristine + Irinotecan (Part A)</arm_group_label>
    <arm_group_label>Olaratumab + Vincristine + Irinotecan (Part B)</arm_group_label>
    <arm_group_label>Olaratumab + Vincristine + Irinotecan (Part C)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Irinotecan</intervention_name>
    <description>Irinotecan administered IV.</description>
    <arm_group_label>Olaratumab + Vincristine + Irinotecan (Part A)</arm_group_label>
    <arm_group_label>Olaratumab + Vincristine + Irinotecan (Part B)</arm_group_label>
    <arm_group_label>Olaratumab + Vincristine + Irinotecan (Part C)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ifosfamide</intervention_name>
    <description>Ifosfamide administered IV.</description>
    <arm_group_label>Olaratumab + Ifosfamide (Part A)</arm_group_label>
    <arm_group_label>Olaratumab + Ifosfamide (Part B)</arm_group_label>
    <arm_group_label>Olaratumab + Ifosfamide (Part C)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The participant must have histological or cytological evidence of a diagnosis of solid
             tumor, excluding lymphomas and melanoma, but including central nervous system (CNS)
             tumors, that is relapsed or refractory, not be amenable to curative treatment.

          -  The participant has the presence of measurable and/or nonmeasurable but evaluable
             disease as defined by the Response Evaluation Criteria In Solid Tumors (RECIST Version
             1.1). Response Assessment in Neuro-Oncology (RANO) Criteria or Macdonald Criteria
             should be used for CNS tumors.

          -  The participant has a Lansky (&lt;16 years of age) or Karnofsky (≥16 years of age)
             performance score of at least 50.

          -  The participant has adequate hematologic, organ, and coagulation function ≤2 weeks (14
             days) prior to first dose of study drug:

               -  Absolute neutrophil count (ANC) ≥750 cubic millimeters (mm³)

               -  Platelets ≥75,000/mm³

               -  Hemoglobin ≥8 grams per deciliter (g/dL)

               -  Total bilirubin (sum of conjugated + unconjugated) ≤1.5 x upper limit of normal
                  (ULN) for age

               -  Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤3.0 x ULN

               -  Serum creatinine is based on age/gender

               -  Adequate coagulation function as defined by International Normalized Ratio ≤1.5
                  or prothrombin time ≤1.5 x ULN, and partial thromboplastin time ≤1.5 x ULN

          -  Both female and male participants of child-bearing potential must agree to use highly
             effective contraceptive precautions during the trial and up to 3 months following the
             last dose of olaratumab, or longer for other study drugs according to their label.

          -  Participants must have fully recovered from the acute toxic effects of all prior
             anticancer therapies or must adhere to post-treatment conditions as follows:

               -  Myelosuppressive chemotherapy

               -  Hematopoietic growth factors

               -  Biologic (anti-neoplastic agent)

               -  Antibody therapy

               -  Radiation

               -  Stem cell infusion without traumatic brain injury

               -  Corticosteroids

        Exclusion Criteria:

          -  Have received treatment within 21 days of the initial dose of olaratumab with an
             investigational product or non-approved use of a drug or device or are concurrently
             enrolled in any other type of medical research judged not to be scientifically or
             medically compatible with this study.

          -  Participants that have had bone marrow or solid organ transplant are excluded.

          -  The participant has an active fungal, bacterial, and/or known severe viral infection
             including human immunodeficiency virus (HIV) or viral (A, B, or C) hepatitis
             (screening is not required).

          -  Female participants who are pregnant or breastfeeding are excluded.

          -  If the participant is to be enrolled in the doxorubicin combination arm, a left
             ventricular dysfunction (LVEF &lt; 50%) or shortening fraction of &lt;27% by echocardiogram
             (either multigated acquisition [MUGA] or echocardiogram [ECHO] are required, not
             both).

          -  Participants that have received prior anthracycline therapy if the participant is to
             be enrolled in the doxorubicin combination arm.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>There may be multiple sites in this clinical trial. 1-877-CTLILLY (1-877-285-4559) or</last_name>
    <phone>1-317-615-4559</phone>
  </overall_contact>
  <location>
    <facility>
      <name>Phoenix Childrens Hospital</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>602-933-0920</phone>
    </contact>
    <investigator>
      <last_name>Pooja Hingorani</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Childrens Hospital of Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90027</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>323-361-2529</phone>
    </contact>
    <investigator>
      <last_name>Leo Mascarenhas</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of California, San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94158</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>415-476-3831</phone>
    </contact>
    <investigator>
      <last_name>Kieuhoa Vo</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Children's Hospital for Cancer and Blood Disorders</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>720-777-6458</phone>
    </contact>
    <investigator>
      <last_name>Margaret Macy</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's National Medical Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010-2970</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>202-476-2800</phone>
    </contact>
    <investigator>
      <last_name>AeRang Kim</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sylvester Comprehensive Cancer Center</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>305-243-4830</phone>
    </contact>
    <investigator>
      <last_name>Matteo Trucco</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>All Childrens Hospital</name>
      <address>
        <city>Saint Petersburg</city>
        <state>Florida</state>
        <zip>33701</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>727-767-2423</phone>
    </contact>
    <investigator>
      <last_name>Peter Shaw</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Riley Hospital for Children</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>317-944-8784</phone>
    </contact>
    <investigator>
      <last_name>Kamnesh Pradhan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dana Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>617-632-5460</phone>
    </contact>
    <investigator>
      <last_name>Steven DuBois</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Minnesota Medical School</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>612-625-8929</phone>
    </contact>
    <investigator>
      <last_name>Brenda Weigel</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Mercy Hospital</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64108</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>816-302-6801</phone>
    </contact>
    <investigator>
      <last_name>Keith August</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cohen Children's Medical Center</name>
      <address>
        <city>New Hyde Park</city>
        <state>New York</state>
        <zip>11040</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>718-470-3460</phone>
    </contact>
    <investigator>
      <last_name>Julie Krystal</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mount Sinai School of Medicine Dermatology Clinical Trials</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>212-241-6756</phone>
    </contact>
    <investigator>
      <last_name>Pamela Merola</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>212-639-5952</phone>
    </contact>
    <investigator>
      <last_name>Emily Slotkin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Levine Children's Hospital</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28203,</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>704-381-6810</phone>
    </contact>
    <investigator>
      <last_name>Chad Jacobsen</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>513-636-4266</phone>
    </contact>
    <investigator>
      <last_name>Brian Turpin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St Jude Childrens Research Hospital</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>901-595-2220</phone>
    </contact>
    <investigator>
      <last_name>Michael Bishop</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232-6307</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>615-936-1762</phone>
    </contact>
    <investigator>
      <last_name>Scott Borinstein</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mary Crowley Cancer Research Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75230</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>972-566-3090</phone>
    </contact>
    <investigator>
      <last_name>Maurizio Ghisoli</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Texas Southwestern Medical Center at Dallas</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75235</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>214-456-2924</phone>
    </contact>
    <investigator>
      <last_name>Theodore Laetsch</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mary Crowley Cancer Research Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75251</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>972-566-6647</phone>
    </contact>
    <investigator>
      <last_name>Maurizio Ghisoli</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Childrens Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>832-824-4632</phone>
    </contact>
    <investigator>
      <last_name>Jodi Muscal</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Utah School of Medicine</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84132</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>801-585-0174</phone>
    </contact>
    <investigator>
      <last_name>Mark Fluchel</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Seattle Children's Hospital Research Foundation</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>206-987-2106</phone>
    </contact>
    <investigator>
      <last_name>Douglas Hawkins</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician.</name>
      <address>
        <city>Chuo Ku</city>
        <zip>104-0045</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Eli Lilly and Company</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Japan</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.lillytrialguide.com/en-US/studies/pediatric-neoplasm%20metastasis/JGDN#?postal=</url>
    <description>Click here for more information about this study: A Study of Olaratumab Alone and in Combination With Standard Chemotherapies in Children With Cancer</description>
  </link>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 29, 2016</study_first_submitted>
  <study_first_submitted_qc>February 4, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 9, 2016</study_first_posted>
  <last_update_submitted>April 4, 2018</last_update_submitted>
  <last_update_submitted_qc>April 4, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 5, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Irinotecan</mesh_term>
    <mesh_term>Isophosphamide mustard</mesh_term>
    <mesh_term>Olaratumab</mesh_term>
    <mesh_term>Camptothecin</mesh_term>
    <mesh_term>Vincristine</mesh_term>
    <mesh_term>Ifosfamide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

